AbbVie Inc.
ABBV Healthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow ABBV
AbbVie Inc. (ABBV) P/S ratio
As of 16 October 2026, AbbVie Inc. (ABBV) trades at a P/S ratio of 7.8×. Over the past ten years it has ranged from 2.9× (August 2019) to 7.8× (October 2026) — the current reading is the highest in ten years. That is above the Drug Manufacturers General industry median of 3.4× and above the Healthcare sector median of 3.4×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 6.6× | 18.44% |
| FY2024 | 5.6× | 7.27% |
| FY2023 | 5.2× | 5.01% |
| FY2022 | 5.0× | 16.16% |
| FY2021 | 4.3× | 9.36% |
| FY2020 | 3.9× | (1.07%) |
| FY2019 | 3.9× | (9.12%) |
| FY2018 | 4.3× | (22.08%) |
| FY2017 | 5.6× | 40.98% |
| FY2016 | 3.9× | (6.24%) |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Jun 2026 | 6.9× | 12.82% |
| Mar 2026 | 6.1× | (7.28%) |
| Dec 2025 | 6.6× | (3.76%) |
| Sep 2025 | 6.9× | 22.05% |
| 42 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| PFE Pfizer Inc. compare | 2.6× |
| AZN AstraZeneca PLC compare | 4.2× |
| NVS Novartis AG compare | 5.1× |
| MRK Merck & Co., Inc. compare | 5.4× |
| AMGN Amgen Inc. compare | 6.1× |
| JNJ Johnson & Johnson compare | 6.2× |
| GILD Gilead Sciences, Inc. compare | 6.4× |
| ABBV AbbVie Inc. | 7.8× |
| LLY Eli Lilly and Company compare | 14.1× |
| Drug Manufacturers General industry median | 3.4× |
| Healthcare sector median | 3.4× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on ABBV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement